The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2020 | Management of B-cell malignancies in the face of COVID-19
Andrew Davies, BSc, BM, MRCP, PhD, of the University of Southampton, Southampton, UK, discusses changes in the treatment and management of B-cell malignancies as a result of the COVID-19 pandemic, such as the use of virtual consultations, and for some patients, changes in chemotherapeutic agents used in order to reduce the negative effects on T-cell function. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).
